KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Equity IncomeGross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Nektar Therapeutics (NKTR) Gross Profit (2016 - 2025)

Nektar Therapeutics has reported Gross Profit over the past 16 years, most recently at $15.0 million for Q4 2025.

  • Quarterly results put Gross Profit at $15.0 million for Q4 2025, up 52.09% from a year ago — trailing twelve months through Dec 2025 was $27.8 million (down 48.3% YoY), and the annual figure for FY2025 was $10.5 million, down 81.37%.
  • Gross Profit for Q4 2025 was $15.0 million at Nektar Therapeutics, up from $1.5 million in the prior quarter.
  • Over the last five years, Gross Profit for NKTR hit a ceiling of $20.7 million in Q2 2021 and a floor of $851000.0 in Q2 2025.
  • Median Gross Profit over the past 5 years was $14.7 million (2023), compared with a mean of $14.1 million.
  • Biggest five-year swings in Gross Profit: surged 68.1% in 2024 and later crashed 93.81% in 2025.
  • Nektar Therapeutics' Gross Profit stood at $18.8 million in 2021, then fell by 16.22% to $15.8 million in 2022, then dropped by 15.63% to $13.3 million in 2023, then dropped by 26.16% to $9.8 million in 2024, then soared by 52.09% to $15.0 million in 2025.
  • The last three reported values for Gross Profit were $15.0 million (Q4 2025), $1.5 million (Q3 2025), and $851000.0 (Q2 2025) per Business Quant data.